Product A

• Ophthalmic Unit Dose

• Approval 2022 •$38M, increasing volume

• 1 generic

Product B

• Otic Unit Dose

• $5.5M, sales to increase due to expansion

• CGT, Approved in Nov’ 2024

Contact us below to learn more!